Cardiff Oncology Inc (CRDF)

Jun 2, 2025, 4:05 PM EDT - 2 days ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

May 14, 2025, 9:05 AM EDT - 21 days ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 8, 2025, 4:05 PM EDT - 27 days ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 2, 2025, 3:35 AM EDT - 4 weeks ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Apr 23, 2025, 4:05 PM EDT - 6 weeks ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 15, 2025, 4:10 PM EDT - 7 weeks ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:05 PM EDT - 7 weeks ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Feb 27, 2025, 9:10 PM EST - 3 months ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 24, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 20, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 18, 2025, 9:19 AM EST - 3 months ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Dec 14, 2024, 9:00 AM EST - 6 months ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Dec 12, 2024, 5:38 AM EST - 6 months ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 10, 2024, 5:05 PM EST - 6 months ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 7:20 AM EST - 6 months ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 6:00 AM EST - 6 months ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Oct 30, 2024, 4:30 PM EDT - 7 months ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 4, 2024, 1:10 PM EDT - 8 months ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Aug 12, 2024, 2:57 PM EDT - 10 months ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 10, 2024, 11:18 AM EDT - 10 months ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Mar 8, 2024, 7:37 PM EST - 1 year ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 6, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Feb 29, 2024, 8:06 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:07 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

Feb 29, 2024, 4:06 PM EST - 1 year ago

Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC

Feb 29, 2024, 4:05 PM EST - 1 year ago

Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)

Feb 26, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Feb 22, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update

Jan 17, 2024, 10:30 AM EST - 1 year ago

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Nov 20, 2023, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 2, 2023, 9:11 PM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Oct 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Sep 27, 2023, 5:56 AM EDT - 1 year ago

Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks

COST MLKN PRGS TRUE

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy

Sep 5, 2023, 8:00 AM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in September

Aug 9, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update

Aug 7, 2023, 4:05 PM EDT - 1 year ago

Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship

May 4, 2023, 4:10 PM EDT - 2 years ago

Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer

Mar 6, 2023, 8:15 AM EST - 2 years ago

Cardiff Oncology Formally Introduces Scientific Advisory Board

Mar 2, 2023, 4:10 PM EST - 2 years ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update